Current Status of Left Ventricular Assist Device Therapy

Mayo Clinic Proceedings

Volumn 91, Issue 7, 2016, Pages 927-940

  Sajgalik, Pavol ^a,b   Grupper, Avishay ^a   Edwards, Brook S ^a   Kushwaha, Sudhir S ^a   Stulak, John M ^a   Joyce, David L ^a   Joyce, Lyle D ^a   Daly, Richard C ^a   Kara, Tomas ^a,b   Schirger, John A ^a  

^a MAYO CLINIC   (United States)

^b ST ANNE S UNIVERSITY HOSPITAL   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; C REACTIVE PROTEIN; CLENBUTEROL; MILRINONE; TUMOR NECROSIS FACTOR; WARFARIN;

CARDIOLOGIST; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR PARAMETERS; CARDIOVASCULAR RISK; CELL THERAPY; CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; EQUIPMENT DESIGN; EVENT FREE SURVIVAL; GASTROINTESTINAL HEMORRHAGE; GENERAL PRACTITIONER; HEART FAILURE; HEART HEMODYNAMICS; HEART RIGHT VENTRICLE FAILURE; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HUMAN; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; INTERNATIONAL NORMALIZED RATIO; LEFT VENTRICULAR ASSIST DEVICE; MEDICAL DECISION MAKING; MEDICAL DEVICE COMPLICATION; MYOCARDIAL ATROPHY; MYOCARDIAL DISEASE; NEW YORK HEART ASSOCIATION CLASS; POSTOPERATIVE CARE; PSYCHOLOGIC ASSESSMENT; PUMP THROMBOSIS; QUALITY OF LIFE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK FACTOR; SURGICAL MORTALITY; SURVIVAL RATE; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; TREATMENT OUTCOME; UNITED STATES; ADVERSE EFFECTS; COMORBIDITY; HEART ASSIST DEVICE; HEART TRANSPLANTATION; PATHOPHYSIOLOGY; STANDARDS; STATISTICS AND NUMERICAL DATA; THROMBOSIS; TRANSPLANTATION;

COMORBIDITY; HEART FAILURE; HEART TRANSPLANTATION; HEART-ASSIST DEVICES; HUMANS; THROMBOSIS; TISSUE AND ORGAN PROCUREMENT;

EID: 84991706726     PISSN: 00256196     EISSN: 19425546     Source Type: Journal    
DOI: 10.1016/j.mayocp.2016.05.002     Document Type: Review

References (120)

1. 1 Levy, D., Kenchaiah, S., Larson, M.G., et al. Long-term trends in the incidence of and survival with heart failure. N Engl J Med 347:18 (2002), 1397–1402.
2. 2 Candrilli, S.D., Kuznik, A., Mendys, P.M., Wilson, D.J., Prevalence and coexistence of cardiovascular comorbidities among the US dyslipidemic population aged ≥ 65 years by lipid-lowering medication use status. Postgrad Med 122:5 (2010), 142–149.
3. 3 Ahn, S.A., Jong, P., Yusuf, S., Bangdiwala, S.I., Pouleur, H.G., Rousseau, M.F., Early versus delayed enalapril in patients with left ventricular systolic dysfunction: impact on morbidity and mortality 15 years after the SOLVD trial. [letter] J Am Coll Cardiol 47:9 (2006), 1904–1905.
4. 4 Otterstad, J.E., Ford, I., The effect of carvedilol in patients with impaired left ventricular systolic function following an acute myocardial infarction: how do the treatment effects on total mortality and recurrent myocardial infarction in CAPRICORN compare with previous beta-blocker trials?. Eur J Heart Fail 4:4 (2002), 501–506.
5. 5 Dargie, H.J., Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet 357:9266 (2001), 1385–1390.
6. 6 Tang, A.S., Wells, G.A., Talajic, M., et al., Resynchronization-Defibrillation for Ambulatory Heart Failure Trial Investigators. Cardiac-resynchronization therapy for mild-to-moderate heart failure. N Engl J Med 363:25 (2010), 2385–2395.
7. 7 Levy, W.C., Mozaffarian, D., Linker, D.T., Farrar, D.J., Miller, L.W., REMATCH Investigators. Can the Seattle Heart Failure Model be used to risk-stratify heart failure patients for potential left ventricular assist device therapy?. J Heart Lung Transplant 28:3 (2009), 231–236.
8. 8 Kuppahally, S.S., Valantine, H.A., Weisshaar, D., et al. Outcome in cardiac recipients of donor hearts with increased left ventricular wall thickness. Am J Transplant 7:10 (2007), 2388–2395.
9. 9 Rose, E.A., Gelijns, A.C., Moskowitz, A.J., et al., Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure (REMATCH) Study Group. Long-term use of a left ventricular assist device for end-stage heart failure. N Engl J Med 345:20 (2001), 1435–1443.
10. 10 Rogers, J.G., Aaronson, K.D., Boyle, A.J., et al., HeartMate II Investigators. Continuous flow left ventricular assist device improves functional capacity and quality of life of advanced heart failure patients. J Am Coll Cardiol 55:17 (2010), 1826–1834.
11. 11 Park, S.J., Tector, A., Piccioni, W., et al. Left ventricular assist devices as destination therapy: a new look at survival. J Thorac Cardiovasc Surg 129:1 (2005), 9–17.
12. 12 Patel, C.B., Alexander, K.M., Rogers, J.G., Mechanical circulatory support for advanced heart failure. Curr Treat Options Cardiovasc Med 12:6 (2010), 549–565.
13. 13 Zimpfer, D., Zrunek, P., Sandner, S., et al. Post-transplant survival after lowering fixed pulmonary hypertension using left ventricular assist devices. Eur J Cardiothorac Surg 31:4 (2007), 698–702.
14. 14 Pagani, F.D., Miller, L.W., Russell, S.D., et al., HeartMate II Investigators. Extended mechanical circulatory support with a continuous-flow rotary left ventricular assist device. J Am Coll Cardiol 54:4 (2009), 312–321.
15. 15 Lietz, K., Miller, L.W., Improved survival of patients with end-stage heart failure listed for heart transplantation: analysis of organ procurement and transplantation network/U.S. United Network of Organ Sharing data, 1990 to 2005. J Am Coll Cardiol 50:13 (2007), 1282–1290.
16. 16 Slaughter, M.S., Meyer, A.L., Birks, E.J., Destination therapy with left ventricular assist devices: patient selection and outcomes. Curr Opin Cardiol 26:3 (2011), 232–236.
17. 17 Starling, R.C., Naka, Y., Boyle, A.J., et al. Results of the post-U.S. Food and Drug Administration-approval study with a continuous flow left ventricular assist device as a bridge to heart transplantation: a prospective study using the INTERMACS (Interagency Registry for Mechanically Assisted Circulatory Support). [published correction appears in J Am Coll Cardiol. 2011;58(20):2142] J Am Coll Cardiol 57:19 (2011), 1890–1898.
18. 18 Aggarwal, S., Pagani, F.D., Bridge to transplantation: current outcomes. J Card Surg 25:4 (2010), 455–461.
19. 19 Feldman, D., Pamboukian, S.V., Teuteberg, J.J., et al. The 2013 International Society for Heart and Lung Transplantation Guidelines for mechanical circulatory support: executive summary. J Heart Lung Transplant 32:2 (2013), 157–187.
20. 20 Slaughter, M.S., Pagani, F.D., Rogers, J.G., et al., HeartMate II Clinical Investigators. Clinical management of continuous-flow left ventricular assist devices in advanced heart failure. J Heart Lung Transplant 29:4, suppl (2010), S1–S39.
21. 21 Slaughter, M.S., Rogers, J.G., Milano, C.A., et al. Advanced heart failure treated with continuous-flow left ventricular assist device. N Engl J Med 361:23 (2009), 2241–2251.
22. 22 Frazier, O.H., Rose, E.A., Oz, M.C., et al., HeartMate LVAS Investigators. Multicenter clinical evaluation of the HeartMate vented electric left ventricular assist system in patients awaiting heart transplantation. J Thorac Cardiovasc Surg 122:6 (2001), 1186–1195.
23. 23 Dembitsky, W.P., Tector, A.J., Park, S., et al. Left ventricular assist device performance with long-term circulatory support: lessons from the REMATCH trial. Ann Thorac Surg 78:6 (2004), 2123–2129.
24. 24 Wieselthaler, G.M., O'Driscoll, G., Jansz, P., Khaghani, A., Strueber, M., HVAD Clinical Investigators. Initial clinical experience with a novel left ventricular assist device with a magnetically levitated rotor in a multi-institutional trial. J Heart Lung Transplant 29:11 (2010), 1218–1225.
25. 25 Wu, L., Weng, Y.G., Dong, N.G., et al. Outcomes of HeartWare Ventricular Assist System support in 141 patients: a single-centre experience. Eur J Cardiothorac Surg 44:1 (2013), 139–145.
26. 26 Slaughter, M.S., Implantation of the HeartWare left ventricular assist device. Semin Thorac Cardiovasc Surg 23:3 (2011), 245–247.
27. 27 Krabatsch, T., Hennig, E., Stepanenko, A., et al. Evaluation of the HeartWare HVAD centrifugal pump for right ventricular assistance in an in vitro model. ASAIO J 57:3 (2011), 183–187.
28. 28 Strueber, M., Larbalestier, R., Jansz, P., et al. Results of the post-market Registry to Evaluate the HeartWare Left Ventricular Assist System (ReVOLVE). J Heart Lung Transplant 33:5 (2014), 486–491.
29. 29 Mussivand, T., Hetzer, R., Vitali, E., et al. Clinical results with an ePTFE inflow conduit for mechanical circulatory support. J Heart Lung Transplant 23:12 (2004), 1366–1370.
30. 30 Cheng, A., Williamitis, C.A., Slaughter, M.S., Comparison of continuous-flow and pulsatile-flow left ventricular assist devices: is there an advantage to pulsatility?. Ann Cardiothorac Surg 3:6 (2014), 573–581.
31. 31 Hall, J.L., Fermin, D.R., Birks, E.J., et al. Clinical, molecular, and genomic changes in response to a left ventricular assist device. J Am Coll Cardiol 57:6 (2011), 641–652.
32. 32 Maltais, S., Jaik, N.P., Feurer, I.D., et al. Mechanical circulatory support and heart transplantation: donor and recipient factors influencing graft survival. Ann Thorac Surg 96:4 (2013), 1252–1258.
33. 33 Thacher, T., Gambillara, V., da Silva, R.F., Silacci, P., Stergiopulos, N., Reduced cyclic stretch, endothelial dysfunction, and oxidative stress: an ex vivo model. Cardiovasc Pathol 19:4 (2010), e91–e98.
34. 34 Baba, A., Dobsak, P., Mochizuki, S., et al. Evaluation of pulsatile and nonpulsatile flow in microvessels of the bulbar conjunctiva in the goat with an undulation pump artificial heart. Artif Organs 27:10 (2003), 875–881.
35. 35 Sezai, A., Shiono, M., Orime, Y., et al. Major organ function under mechanical support: comparative studies of pulsatile and nonpulsatile circulation. Artif Organs 23:3 (1999), 280–285.
36. 36 Presson, R.G. Jr., Baumgartner, W.A. Jr., Peterson, A.J., Glenny, R.W., Wagner, W.W. Jr., Pulmonary capillaries are recruited during pulsatile flow. J Appl Physiol (1985) 92:3 (2002), 1183–1190.
37. 37 Ootaki, C., Yamashita, M., Ootaki, Y., et al. Reduced pulsatility induces periarteritis in kidney: role of the local renin-angiotensin system. J Thorac Cardiovasc Surg 136:1 (2008), 150–158.
38. 38 Netuka, I., Sood, P., Pya, Y., et al. Fully magnetically levitated left ventricular assist system for treating advanced Hf: a multicenter study. J Am Coll Cardiol 66:23 (2015), 2579–2589.
39. 39 Jessup, M., Abraham, W.T., Casey, D.E., et al. 2009 Focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines; developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 119:14 (2009), 1977–2016.
40. 40 Peura, J.L., Colvin-Adams, M., Francis, G.S., et al. American Heart Association Heart Failure and Transplantation Committee of the Council on Clinical Cardiology Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation, Council on Cardiovascular Disease in the Young; Council on Cardiovascular Nursing; Council on Cardiovascular Radiology and Intervention; and Council on Cardiovascular Surgery and Anesthesia. Recommendations for the use of mechanical circulatory support: device strategies and patient selection; a scientific statement from the American Heart Association. Circulation 126:22 (2012), 2648–2667.
41. 41 Lund, L.H., Matthews, J., Aaronson, K., Patient selection for left ventricular assist devices. Eur J Heart Fail 12:5 (2010), 434–443.
42. 42 Wilson, S.R., Mudge, G.H. Jr., Stewart, G.C., Givertz, M.M., Evaluation for a ventricular assist device: selecting the appropriate candidate. Circulation 119:16 (2009), 2225–2232.
43. 43 Oz, M.C., Rose, E.A., Slater, J., Kuiper, J.J., Catanese, K.A., Levin, H.R., Malignant ventricular arrhythmias are well tolerated in patients receiving long-term left ventricular assist devices. J Am Coll Cardiol 24:7 (1994), 1688–1691.
44. 44 Guerra, F., Flori, M., Bonelli, P., Patani, F., Capucci, A., Electrical storm and heart failure worsening in implantable cardiac defibrillator patients. Europace 17:2 (2015), 247–254.
45. 45 Verma, A., Kilicaslan, F., Marrouche, N.F., et al. Prevalence, predictors, and mortality significance of the causative arrhythmia in patients with electrical storm. J Cardiovasc Electrophysiol 15:11 (2004), 1265–1270.
46. 46 Topilsky, Y., Pereira, N.L., Shah, D.K., et al. Left ventricular assist device therapy in patients with restrictive and hypertrophic cardiomyopathy. Circ Heart Fail 4:3 (2011), 266–275.
47. 47 Joyce, D.L., Crow, S.S., John, R., et al. Mechanical circulatory support in patients with heart failure secondary to transposition of the great arteries. J Heart Lung Transplant 29:11 (2010), 1302–1305.
48. 48 Alba, A.C., Rao, V., Ivanov, J., Ross, H.J., Delgado, D.H., Usefulness of the INTERMACS scale to predict outcomes after mechanical assist device implantation. J Heart Lung Transplant 28:8 (2009), 827–833.
49. 49 Kirklin, J.K., Naftel, D.C., Pagani, F.D., et al. Sixth INTERMACS annual report: a 10,000-patient database. J Heart Lung Transplant 33:6 (2014), 555–564.
50. 50 Lietz, K., Long, J.W., Kfoury, A.G., et al. Outcomes of left ventricular assist device implantation as destination therapy in the post-REMATCH era: implications for patient selection. Circulation 116:5 (2007), 497–505.
51. 51 Jorde, U.P., Kushwaha, S.S., Tatooles, A.J., et al. Results of the destination therapy post-Food and Drug Administration approval study with a continuous flow left ventricular assist device: a prospective study using the INTERMACS registry (Interagency Registry for Mechanically Assisted Circulatory Support). J Am Coll Cardiol 63:17 (2014), 1751–1757.
52. 52 Lietz, K., Miller, L.W., Patient selection for left-ventricular assist devices. Curr Opin Cardiol 24:3 (2009), 246–251.
53. 53 Altimir, S., Lupón, J., González, B., et al. Sex and age differences in fragility in a heart failure population. Eur J Heart Fail 7:5 (2005), 798–802.
54. 54 Welsby, I.J., Um, J., Milano, C.A., Ortel, T.L., Arepally, G., Plasmapheresis and heparin reexposure as a management strategy for cardiac surgical patients with heparin-induced thrombocytopenia. Anesth Analg 110:1 (2010), 30–35.
55. 55 Schaffer, J.M., Arnaoutakis, G.J., Allen, J.G., et al. Bleeding complications and blood product utilization with left ventricular assist device implantation. Ann Thorac Surg 91:3 (2011), 740–747.
56. 56 Holdy, K., Dembitsky, W., Eaton, L.L., et al. Nutrition assessment and management of left ventricular assist device patients. J Heart Lung Transplant 24:10 (2005), 1690–1696.
57. 57 Zahr, F., Genovese, E., Mathier, M., et al. Obese patients and mechanical circulatory support: weight loss, adverse events, and outcomes. Ann Thorac Surg 92:4 (2011), 1420–1426.
58. 58 Coyle, L.A., Ising, M.S., Gallagher, C., et al. Destination therapy: one-year outcomes in patients with a body mass index greater than 30. Artif Organs 34:2 (2010), 93–97.
59. 59 Brewer, R.J., Lanfear, D.E., Sai-Sudhakar, C.B., et al. Extremes of body mass index do not impact mid-term survival after continuous-flow left ventricular assist device implantation. J Heart Lung Transplant 31:2 (2012), 167–172.
60. 60 Miller, L.W., Guglin, M., Patient selection for ventricular assist devices: a moving target. J Am Coll Cardiol 61:12 (2013), 1209–1221.
61. 61 Park, S.J., Liao, K.K., Segurola, R., Madhu, K.P., Miller, L.W., Management of aortic insufficiency in patients with left ventricular assist devices: a simple coaptation stitch method (Park's stitch). J Thorac Cardiovasc Surg 127:1 (2004), 264–266.
62. 62 De Praetere, H., Jacobs, S., Rega, F., Droogne, W., Meyns, B., Can a central stitch over the Arantius' nodules provide a solution for preoperative severe native AI in LVAD patients. Int J Artif Organs 36:3 (2013), 220–224.
63. 63 Deo, S.V., Hasin, T., Altarabsheh, S.E., et al. Concomitant tricuspid valve repair or replacement during left ventricular assist device implant demonstrates comparable outcomes in the long term. J Card Surg 27:6 (2012), 760–766.
64. 64 University of Washington. Seattle Heart Failure Model. Universit of Washington website. http://depts.washington.edu/shfm/. Accessed March 23, 2015.
65. 65 Koelling, T.M., Joseph, S., Aaronson, K.D., Heart Failure Survival Score continues to predict clinical outcomes in patients with heart failure receiving beta-blockers. J Heart Lung Transplant 23:12 (2004), 1414–1422.
66. 66 Levy, W.C., Mozaffarian, D., Linker, D.T., et al. The Seattle Heart Failure Model: prediction of survival in heart failure. Circulation 113:11 (2006), 1424–1433.
67. 67 Lee, D.S., Austin, P.C., Rouleau, J.L., Liu, P.P., Naimark, D., Tu, J.V., Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model. JAMA 290:19 (2003), 2581–2587.
68. 68 Senni, M., Santilli, G., Parrella, P., et al. A novel prognostic index to determine the impact of cardiac conditions and co-morbidities on one-year outcome in patients with heart failure. Am J Cardiol 98:8 (2006), 1076–1082.
69. 69 Metra, M., Ponikowski, P., Dickstein, K., et al., Heart Failure Association of the European Society of Cardiology. Advanced chronic heart failure: a position statement from the Study Group on Advanced Heart Failure of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 9:6-7 (2007), 684–694.
70. 70 Pocock, S.J., McMurray, J.V., Dobson, J., et al. Weight loss and mortality risk in patients with chronic heart failure in the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) programme. Eur Heart J 29:21 (2008), 2641–2650.
71. 71 Jaarsma, T., Beattie, J.M., Ryder, M., et al., Advanced Heart Failure Study Group of the HFA of the ESC. Palliative care in heart failure: a position statement from the palliative care workshop of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 11:5 (2009), 433–443.
72. 72 Pagani, F.D., Milano, C.A., Tatooles, A.J., et al. HeartWare HVAD for the treatment of patients with advanced heart failure ineligible for cardiac transplantation: results of the ENDURANCE Destination Therapy Trial. J Heart Lung Transplant, 34(4, suppl), 2015, S9.
73. 73 Kirklin, J.K., Naftel, D.C., Kormos, R.L., et al. Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) analysis of pump thrombosis in the HeartMate II left ventricular assist device. J Heart Lung Transplant 33:1 (2014), 12–22.
74. 74 Rogers, J.G., Boyle, A.J., O'Connell, J.B., et al. Risk assessment and comparative effectiveness of left ventricular assist device and medical management in ambulatory heart failure patients: design and rationale of the ROADMAP clinical trial. Am Heart J 169:2 (2015), 205–210.e20.
75. 75 Stewart, G.C., Stevenson, L.W., INTERMACS and MedaMACS: how will they guide future therapy?. Curr Cardiol Rep, 15(9), 2013, 394.
76. 76 Mancini, D., Lietz, K., Selection of cardiac transplantation candidates in 2010. Circulation 122:2 (2010), 173–183.
77. 77 Aurora, P., Edwards, L.B., Christie, J., et al. Registry of the International Society for Heart and Lung Transplantation: eleventh official pediatric lung and heart/lung transplantation report—2008. J Heart Lung Transplant 27:9 (2008), 978–983.
78. 78 Butler, J., Geisberg, C., Howser, R., et al. Relationship between renal function and left ventricular assist device use. Ann Thorac Surg 81:5 (2006), 1745–1751.
79. 79 Slaughter, M.S., Long-term continuous flow left ventricular assist device support and end-organ function: prospects for destination therapy. J Card Surg 25:4 (2010), 490–494.
80. 80 Radovancevic, B., Vrtovec, B., de Kort, E., Radovancevic, R., Gregoric, I.D., Frazier, O.H., End-organ function in patients on long-term circulatory support with continuous- or pulsatile-flow assist devices. J Heart Lung Transplant 26:8 (2007), 815–818.
81. 81 Assad-Kottner, C., Chen, D., Jahanyar, J., et al. The use of continuous milrinone therapy as bridge to transplant is safe in patients with short waiting times. J Card Fail 14:10 (2008), 839–843.
82. 82 Sasaki, H., Mitchell, J.D., Jessen, M.E., et al. Bridge to heart transplantation with left ventricular assist device versus inotropic agents in status 1 patients. J Card Surg 24:6 (2009), 756–762.
83. 83 Wozniak, C.J., Stehlik, J., Baird, B.C., et al. Ventricular assist devices or inotropic agents in status 1A patients? survival analysis of the United Network of Organ Sharing database. Ann Thorac Surg 97:4 (2014), 1364–1371.
84. 84 Holman, W.L., Kormos, R.L., Naftel, D.C., et al. Predictors of death and transplant in patients with a mechanical circulatory support device: a multi-institutional study. J Heart Lung Transplant 28:1 (2009), 44–50.
85. 85 Lietz, K., Destination therapy: patient selection and current outcomes. J Card Surg 25:4 (2010), 462–471.
86. 86 Swetz, K.M., Freeman, M.R., AbouEzzeddine, O.F., et al. Palliative medicine consultation for preparedness planning in patients receiving left ventricular assist devices as destination therapy. Mayo Clin Proc 86:6 (2011), 493–500.
87. 87 Daneshmand, M.A., Rajagopal, K., Lima, B., et al. Left ventricular assist device destination therapy versus extended criteria cardiac transplant. Ann Thorac Surg 89:4 (2010), 1205–1209.
88. 88 Crow, S., Milano, C., Joyce, L., et al. Comparative analysis of von Willebrand factor profiles in pulsatile and continuous left ventricular assist device recipients. ASAIO J 56:5 (2010), 441–445.
89. 89 Crow, S., Chen, D., Milano, C., et al. Acquired von Willebrand syndrome in continuous-flow ventricular assist device recipients. Ann Thorac Surg 90:4 (2010), 1263–1269.
90. 90 Klovaite, J., Gustafsson, F., Mortensen, S.A., Sander, K., Nielsen, L.B., Severely impaired von Willebrand factor-dependent platelet aggregation in patients with a continuous-flow left ventricular assist device (HeartMate II). J Am Coll Cardiol 53:23 (2009), 2162–2167.
91. 91 Pereira, N.L., Chen, D., Kushwaha, S.S., Park, S.J., Discontinuation of antithrombotic therapy for a year or more in patients with continuous-flow left ventricular assist devices. Interact Cardiovasc Thorac Surg 11:4 (2010), 503–505.
92. 92 Starling, R.C., Moazami, N., Silvestry, S.C., et al. Unexpected abrupt increase in left ventricular assist device thrombosis. N Engl J Med 370:1 (2014), 33–40.
93. 93 Shah, P., Mehta, V.M., Cowger, J.A., Aaronson, K.D., Pagani, F.D., Diagnosis of hemolysis and device thrombosis with lactate dehydrogenase during left ventricular assist device support. J Heart Lung Transplant 33:1 (2014), 102–104.
94. 94 Uriel, N., Morrison, K.A., Garan, A.R., et al. Development of a novel echocardiography ramp test for speed optimization and diagnosis of device thrombosis in continuous-flow left ventricular assist devices: the Columbia ramp study. J Am Coll Cardiol 60:18 (2012), 1764–1775.
95. 95 Fine, N.M., Topilsky, Y., Oh, J.K., et al. Role of echocardiography in patients with intravascular hemolysis due to suspected continuous-flow LVAD thrombosis. J Am Coll Cardiol Img 6:11 (2013), 1129–1140.
96. 96 Mishkin, J.D., Enriquez, J.R., Meyer, D.M., et al. Utilization of cardiac computed tomography angiography for the diagnosis of left ventricular assist device thrombosis. Circ Heart Fail 5:2 (2012), e27–e29.
97. 97 Stulak, J.M., Maltais, S., A different perspective on thrombosis and the HeartMate II. [letter] N Engl J Med 370:15 (2014), 1467–1468.
98. 98 Emani, S., Keebler, M., Ransom, J.M., et al. Prevention of HeartMate II pump thrombosis - recommendations and preliminary observations from the PREVENT study. [abstract] Circulation, 132, 2015, A16405.
99. 99 Topilsky, Y., Oh, J.K., Shah, D.K., et al. Echocardiographic predictors of adverse outcomes after continuous left ventricular assist device implantation. J Am Coll Cardiol Img 4:3 (2011), 211–222.
100. 100 Drakos, S.G., Janicki, L., Horne, B.D., et al. Risk factors predictive of right ventricular failure after left ventricular assist device implantation. Am J Cardiol 105:7 (2010), 1030–1035.
101. 101 Liden, H., Haraldsson, A., Ricksten, S.E., Kjellman, U., Wiklund, L., Does pretransplant left ventricular assist device therapy improve results after heart transplantation in patients with elevated pulmonary vascular resistance?. Eur J Cardiothorac Surg 35:6 (2009), 1029–1034.
102. 102 Baumwol, J., Macdonald, P.S., Keogh, A.M., et al. Right heart failure and “failure to thrive” after left ventricular assist device: clinical predictors and outcomes. J Heart Lung Transplant 30:8 (2011), 888–895.
103. 103 Lee, S., Kamdar, F., Madlon-Kay, R., et al. Effects of the HeartMate II continuous-flow left ventricular assist device on right ventricular function. J Heart Lung Transplant 29:2 (2010), 209–215.
104. 104 Kasirajan, V., Tang, D.G., Katlaps, G.J., Shah, K.B., The total artificial heart for biventricular heart failure and beyond. Curr Opin Cardiol 27:3 (2012), 301–307.
105. 105 Maybaum, S., Mancini, D., Xydas, S., et al., LVAD Working Group. Cardiac improvement during mechanical circulatory support: a prospective multicenter study of the LVAD Working Group. Circulation 115:19 (2007), 2497–2505.
106. 106 Birks, E.J., Tansley, P.D., Hardy, J., et al. Left ventricular assist device and drug therapy for the reversal of heart failure. N Engl J Med 355:18 (2006), 1873–1884.
107. 107 Birks, E.J., George, R.S., Hedger, M., et al. Reversal of severe heart failure with a continuous-flow left ventricular assist device and pharmacological therapy: a prospective study. Circulation 123:4 (2011), 381–390.
108. 108 Barton, P.J., Felkin, L.E., Birks, E.J., et al. Myocardial insulin-like growth factor-I gene expression during recovery from heart failure after combined left ventricular assist device and clenbuterol therapy. Circulation 112:9, suppl (2005), I46–I50.
109. 109 Slaughter, M.S., Giridharan, G.A., Tamez, D., et al. Transapical miniaturized ventricular assist device: design and initial testing. J Thorac Cardiovasc Surg 142:3 (2011), 668–674.
110. 110 Meyns, B., Klotz, S., Simon, A., et al. Proof of concept: hemodynamic response to long-term partial ventricular support with the synergy pocket micro-pump. J Am Coll Cardiol 54:1 (2009), 79–86.
111. 111 Meyns, B.P., Simon, A., Klotz, S., et al. Clinical benefits of partial circulatory support in New York Heart Association class IIIB and early class IV patients. Eur J Cardiothorac Surg 39:5 (2011), 693–698.
112. 112 Asgari, S.S., Bonde, P., Implantable physiologic controller for left ventricular assist devices with telemetry capability. J Thorac Cardiovasc Surg 147:1 (2014), 192–202.
113. 113 Kishimoto, Y., Takewa, Y., Arakawa, M., et al. Development of a novel drive mode to prevent aortic insufficiency during continuous-flow LVAD support by synchronizing rotational speed with heartbeat. J Artif Organs 16:2 (2013), 129–137.
114. 114 Fujita, J., Itabashi, Y., Seki, T., et al. Myocardial cell sheet therapy and cardiac function. Am J Physiol Heart Circ Physiol 303:10 (2012), H1169–H1182.
115. 115 Ascheim, D.D., Gelijns, A.C., Goldstein, D., et al. Mesenchymal precursor cells as adjunctive therapy in recipients of contemporary left ventricular assist devices. Circulation 129:22 (2014), 2287–2296.
116. 116 Kron, I.L., LaPar, D.J., Horvath, K.A., CTSN Investigators and the American Association for Thoracic Surgery Scientific Affairs and Government Relations Committee. Cardiothoracic Surgical Trials Network: evidence-based surgery. [editorial] J Thorac Cardiovasc Surg 151:1 (2016), 28–29.
117. 117 National Heart, Lung, and Blood Institute. Safety & Efficacy of Intramyocardial Injection of Mesenchymal Precursor Cells on Myocardial Function in LVAD Recipients. ClinicalTrials.gov identifier: NCT02362646. ClinicalTrials.gov website. https://clinicaltrials.gov/ct2/show/NCT02362646?term=NCT02362646&rank=1. Published February 9, 2015. Updated May 5, 2016. Accessed May 12, 2016.
118. 118 Fujita, S., Sano, M., Treatment of the ventricular tachycardia with engraftment of pluripotent stem cells-derived cardiomyocytes. [editorial] J Mol Cell Cardiol 53:1 (2012), 3–5.
119. 119 Shiba, Y., Fernandes, S., Zhu, W.Z., Filice, D., Muskheli, V., Kim, J., et al. Human ES-cell-derived cardiomyocytes electrically couple and suppress arrhythmias in injured hearts. [letter] Nature 489:7415 (2012), 322–325.
120. 120 Thompson, S.A., Burridge, P.W., Lipke, E.A., Shamblott, M., Zambidis, E.T., Tung, L., Engraftment of human embryonic stem cell derived cardiomyocytes improves conduction in an arrhythmogenic in vitro model. J Mol Cell Cardiol 53:1 (2012), 15–23.